Chloroquine

Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa

Retrieved on: 
Friday, September 15, 2023
Infection, Patent, Travel, College, Parasitism, Orbital Technologies Commercial Space Station, Drug discovery, Clinical trial, Enzyme, Malaria, African, Research, Fever, Open Philanthropy (organization), Chronic myelogenous leukemia, Pharmacotherapy, Low, Drug resistance, Death, Protein, Rupture, Philip B. Low, Novartis, Developed country, Patient, Philanthropy, Blood, Cancer, Chloroquine, Growth, College of Science (Northeastern University), Disease, Vaccine, Pharmaceutical industry, Chemistry, Purdue University

While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug-resistant malaria.

Key Points: 
  • While studying how malaria propagates in human blood, Low and his research team discovered that the cancer drug therapy imatinib is effective in the treatment of drug-resistant malaria.
  • Trials in Southeast Asia showed that imatinib, when combined with the customary malaria therapy, clears all malaria parasites from 90% of patients within 48 hours and 100% of patients within three days .
  • Open Philanthropy has awarded Low $600,000 for a larger clinical trial in Southeast Asia to validate his previous trials.
  • His work also receives support from the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery .

Hesperos Scientists Publish a New Study in Scientific Reports Titled: "Development of a Human Malaria-on-a-Chip Disease Model for Drug Efficacy and Off-Target Toxicity Evaluation"

Retrieved on: 
Wednesday, July 5, 2023
Other Health, Research, General Health, Pharmaceutical, Hardware, Technology, Science, Nanotechnology, Biotechnology, Other Technology, Other Science, Health, Red, Drug development, Failure, Medicines for Malaria Venture, Parasitism, Fever, Skin, Endothelium, Woman, Animal, W2, Spleen, MMV, Scientific Reports, Drug discovery, Plasmodium falciparum, Nausea, Liver, Chloroquine, Parasitemia, Behavior, World Health Organization, Disease, Vaccine, Medical device, Nature, Malaria, Plasmodium

In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.

Key Points: 
  • In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.
  • Through their efforts they developed a human-based model to study the disease pathology and therapeutic effects in a pre-clinical platform.
  • This microfluidic platform connects human liver, spleen, and endothelium with recirculating human erythrocytes in a controlled, self-contained platform.
  • This new approach to the evaluation of Plasmodium falciparum and anti-malarial therapeutics is executed in a realistic human model.

Prescription drugs' fine print is important – a toxicologist explains how to decode package inserts to take medications safely and increase their effectiveness

Retrieved on: 
Monday, April 24, 2023
Food, Fungal infection, Half-life, Bile, Cholesterol, Pharmacodynamics, Enzyme, Pharmacokinetics, Human, Absorption, Bangladesh Technical Education Board, Prodrug, Science, Plasma protein binding, Protein, Metabolism, Patient, Time, CYP, Blood, LDL, HMG-CoA, Liver, Chloroquine, Health, Safety, Pharmaceutical industry, Medical device, Birth control, Generic drug, Animal feed, Atorvastatin

With approximately 1.3 million emergency department visits in the U.S. caused by adverse drug events each year, patient education is becoming increasingly important.

Key Points: 
  • With approximately 1.3 million emergency department visits in the U.S. caused by adverse drug events each year, patient education is becoming increasingly important.
  • All prescription drugs come with instructions on how to safely and effectively use them.
  • Depending on the medication, there may be several types of information included: the patient package insert, medication guide and instructions for use.

What can I learn from package inserts?

    • An often overlooked part of the package insert is the prescribing information.
    • Though written primarily for health care professionals, it contains a wealth of information regarding the ways in which the medication interacts with the body.
    • If you’d like to follow along, a copy of the prescription information for Lipitor can be found here.

How does the drug work?

    • Pharmacodynamics refers to “what the drug does to the body,” which includes the mechanism of action as well as how other factors like drug concentration influences its effects.
    • First, the liver is the primary site that produces cholesterol in the body and the area the drug is meant to target.
    • And third, the drug increases the number of LDL cholesterol receptors on cell surfaces, ultimately increasing the catabolism, or metabolic breakdown, of LDL cholesterol.

Where does the drug go in my body?

    • The pharmacokinetics of a drug are determined by factors related to the chemical itself and the person taking the medication.
    • For Lipitor, the prescription insert does not specifically say where the drug goes in the body, but it does note that the volume of distribution is 381 liters.
    • On the other hand, chloroquine, an antimalarial drug that enters body fat, has a value of 15,000 liters.

Does the drug cause the effects or its byproducts?

    • Though the therapeutic effects of most drugs come from the chemical compound it’s made of, many break down into active metabolites in the body that also have some relevant biological effects.
    • Some medications are administered in an inactive form called a prodrug that the body converts into metabolites with the desired therapeutic effects.

How long will the drug be in my system?

    • Information about a drug’s half-life is found in the “Excretion” subsection under “Pharmacokinetics.” The half-life for Lipitor is approximately 14 hours.
    • This means that the drug’s effects may last even after the drug itself is out of your system.

Why do I need to take medications with food or at certain times?

    • For Lipitor specifically, the answer to this question can be found in the “Absorption” subsection under “Pharmacokinetics.” Food decreases the rate and extent of Lipitor’s absorption but doesn’t significantly affect LDL cholesterol reduction.
    • The upshot of all of this is written on the drug label on the outside of the package: Lipitor can be taken with or without food.

Why does my doctor ask about other drugs I’m taking?

    • For instance, two drugs may rely on the same enzyme system in the body to break them down.
    • Taking them at the same time can ultimately lead to higher-than-anticipated levels of either or both drugs in the body.

Drug Combination Restores Ability of Leading Treatment to Signal for Death of Blood Cancer Cells

Retrieved on: 
Monday, April 24, 2023
Albert Einstein College of Medicine, Hermann, University, Mitophagy, Mitochondrion, Leukemia, NYU, Clinical trial, Bone marrow, Cancer Discovery (journal), Cancer, New York University Grossman School of Medicine, Research, MD Anderson Cancer Center, Cell, Doctor of Philosophy, National Institutes of Health, AstraZeneca, Bangladesh Technical Education Board, Hematopoietic stem cell transplantation, Acute myeloid leukemia, Rutgers University, NYU Langone Health, Drug resistance, Death, Patent, Patient, Pathology, MFN2, Publishing, BH3, Mouse, United Kingdom, Chloroquine, Diagnosis, Gene, Venetoclax, Pharmaceutical industry, Vaccine, Elias C. Aifantis

NEW YORK, April 24, 2023 /PRNewswire/ -- Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs' effects within a year.

Key Points: 
  • This process of "programmed cell death" often goes wrong in cancer.
  • Damaged mitochondria can also undergo a form of "self-eating" termed mitophagy that prevents them from sending "death signals."
  • Additional testing in cancer cells engineered to lack MFN2 showed increased sensitivity to drugs similar to venetoclax compared with cells that had functional MFN2.
  • Acute myeloid leukemia, the most common form of adult leukemia, originates in the bone marrow cells and involves the rapid buildup of abnormal blood cells.

Global Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Retrieved on: 
Thursday, December 22, 2022
Ipca Laboratories, Plasmodium malariae, World Health Organization, Hospital pharmacy, Merck & Co., E-commerce, Inc., Overalls, GlaxoSmithKline, Sun Pharma, Administration, Quinine, Treatment, WHO, Intravenous therapy, Inhalation, Plasmodium falciparum, Growth, Mefloquine, Risk, Ranbaxy Laboratories, Safety, Distribution, Plasmodium knowlesi, Death, Oral, Prevalence, Government, Novartis, Plasmodium vivax, Research, Strides Pharma Science Limited, Plasmodium ovale, Fine chemical, Pharmaceutical industry, Medical device, Dietary supplement, Tutoring, Forecast, Chloroquine, Malaria, Amodiaquine, Hydroxychloroquine, Pyrimethamine, Proguanil

View original content:https://www.prnewswire.com/news-releases/global-antimalarial-drugs-marke...

Key Points: 
  • Additionally, rise in malaria death cases, especially in developing nations are also fueling the growth of antimalarial drugs market.
  • Based on route of administration, the global antimalarial drugs market is segmented into oral, powder inhalation and intravenous administration.
  • • To analyze and forecast the market size of global antimalarial drugs market.
  • In this report, global antimalarial drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    • Global Antimalarial Drugs Market, By Drug Type:

Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)

Retrieved on: 
Tuesday, July 19, 2022
Research, Infectious Diseases, Hospitals, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Nausea, Adult, History, Severe acute respiratory syndrome coronavirus 2, Anaphylaxis, Shivering, AST, RNA, Arm, Disease, Hypersensitivity, Patient, Tachycardia, Hypertension, Safety, Perspiration, JPA, Breathe Me, Pneumonia, Dose, World, ECMO, COVID-19, Ventilation, Drug, Hypotension, Fever, Hydroxychloroquine, Chloroquine, Human, Hypoxia, Hospital, Adolescence, Contraindication, Risk, Kidney failure, Gilead Sciences, Effectiveness, Angioedema, Bradycardia, European Commission, Wheeze, Death, Rash, Omicron, ALT, ULN, HIV disease progression rates, Diagnosis, Hepatitis, Therapy, EGFR, Royal commission, Maintenance, Pharmaceutical industry, Medical device, EU, Remdesivir

Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.

Key Points: 
  • Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.
  • As new SARS-CoV-2 variants of concern emerge around the world, Gilead continuously evaluates the effectiveness of Veklury against viral variants.
  • Veklury, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, GIST, MEK, COVID-19, Association, NASDAQ, Patient, LinkedIn, U.S. Securities and Exchange Commission, Colorectal cancer, Large-cell lung carcinoma, American Association, FDA, Huntsman Cancer Institute, Drug development, Feedback, Annual report, Private Securities Litigation Reform Act, RAF, Phosphorylation, Company, View, Melanoma, Pharmacokinetics, LLC, Chloroquine, United Kingdom, RAS, SEC, American Association for Cancer Research, ULK, Safety, KRAS, Cancer, Drug resistance, Neoplasm, Union, AACR, Autophagy, Pharmaceutical industry, Vaccine, Medical imaging, Dermatology, Twitter, NSCLC

of Dermatology, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute.

Key Points: 
  • of Dermatology, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute.
  • Results from the preclinical studies showed that KRASG12C inhibitors, sotorasib and adagrasib, activate ULK-mediated autophagy as an adaptive treatment resistance mechanism.
  • Results demonstrated that DCC-3116 in combination with sotorasib and with adagrasib translated to deeper and longer tumor regressions in vivo.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

Retrieved on: 
Friday, February 11, 2022
Biotechnology, FDA, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials, Nasdaq, Emergent virus, EMA, Hospital, AST, Patient, Acute kidney injury, Clinical research, Food, EUA, Extracorporeal membrane oxygenation, Hepatitis, Urine, Risk, ALT, Science, Hematology, Human, HIV disease progression rates, Subclinical infection, Death, Șaeș, ULN, Hyperglycemia, Atrium, Chemistry, Safety, Alanine transaminase, ECMO, Virus, Kidney failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chloroquine, Constipation, FDA, Maintenance, Plasma, Nausea, Infection, FAPP, Pharmacokinetics, High-dependency unit, Disease, Effectiveness, Gilead Sciences, Emergency Use Authorization, Diagnosis, Hydroxychloroquine, Severe acute respiratory syndrome coronavirus 2, COVID-19, Conference, EGFR, AES, Fever, Pharmaceutical industry, Medical device, Remdesivir, MD, the CARAVAN Study (GS-US-540-5823, Gilead Sciences, THE CARAVAN STUDY (GS-US-540-5823, GILEAD SCIENCES

This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16.

Key Points: 
  • This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16.
  • These latest data demonstrate that Veklury was generally well tolerated among pediatric patients hospitalized with COVID-19 with a high proportion of participants showing clinical improvement and recovery.
  • Of the 53 pediatric patients enrolled in the study, no new safety signals were apparent for Veklury.
  • Please see below for more information on the approved use of Veklury and the EUA for pediatric patients.

Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

Retrieved on: 
Friday, February 11, 2022
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Nasdaq, History, Bradycardia, Hypotension, AST, Patient, Rash, Food, ALT, EMS, Risk, Science, Dose, Adolescence, Breathe Me, Human, Research, HIV disease progression rates, Hypoxia, Wheeze, RNA, Death, Shanda, ULN, Anaphylaxis, Fever, ECMO, Kidney failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Method, Chloroquine, WA1, Contraindication, FDA, Hypertension, Tachycardia, Angioedema, Perspiration, Allergy, Maintenance, Nausea, Shivering, Disease, Effectiveness, Senior, Delta, Virology, Alpha, Gilead Sciences, Hospital, Diagnosis, Hydroxychloroquine, Severe acute respiratory syndrome coronavirus 2, COVID-19, Hepatitis, Hypersensitivity, EGFR, Pharmaceutical industry, Medical device, Omicron, Remdesivir

The study analyzed in vitro antiviral activity by two methods to understand the susceptibility of ten major SARS-CoV-2 variants to Veklury.

Key Points: 
  • The study analyzed in vitro antiviral activity by two methods to understand the susceptibility of ten major SARS-CoV-2 variants to Veklury.
  • The study results showed similar activity of Veklury against the variants and an early ancestral A lineage isolate detected in Seattle, WA (WA1 strain).
  • Further characterization confirmed that none of the few identified nsp12 mutations prevalent in some of the SARS-CoV-2 variants affects the virus susceptibility to Veklury.
  • Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.

Failure of National Pandemic Plan Examined in the Journal of American Physicians and Surgeons

Retrieved on: 
Tuesday, September 21, 2021
COVID-19, Chloroquine, Trump administration political interference with science agencies, Severe acute respiratory syndrome coronavirus, AAPS, Patient, Association, Physician, Hydroxychloroquine, Association of American Physicians and Surgeons, Government, Coronavirus, EUA, Disease, Journal, Human, HCQ, Task force, SARS, IND, Presidency of Donald Trump, Emergency Use Authorization, GLOBE, Pharmaceutical industry

Americans lives have been tragically disrupted and permanently altered by the COVID-19 pandemic.

Key Points: 
  • Americans lives have been tragically disrupted and permanently altered by the COVID-19 pandemic.
  • The U.S. has had a validated National Pandemic Response Plan since 2000, and it was updated in 2017.
  • This virus, SHCO14-CoV, was analogous to the 2003 SARS virus, and was capable of jumping directly from bats to humans.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.